Economy/Home · Economy

[Breaking] AprilBio Signs Material Transfer Contract Worth 599.17 Million Won with U.S.-Based Evommune for EVO301 MCB

AprilBio announced that it has signed a material transfer contract with U.S.-based Evommune covering EVO301-related materials, including the MCB (Master Cell Bank). The total contract value is $431,128.17. According to the regulatory filing, applying the exchange rate as of August 21, 2026 (1,393 w

Oseong Kwon
Staff Reporter
3 min read
[Breaking] AprilBio Signs Material Transfer Contract Worth 599.17 Million Won with U.S.-Based Evommune for EVO301 MCB
CBC News

AprilBio announced that it has signed a material transfer contract with U.S.-based Evommune covering EVO301-related materials, including the MCB (Master Cell Bank).

The total contract value is $431,128.17. According to the regulatory filing, applying the exchange rate as of August 21, 2026 (1,393 won per dollar), the contract amount comes to 599,168,540 won, equivalent to approximately 27.6% of the company's previous-year revenue of 2.172 billion won.

The subject of the contract is EVO301-related materials held by AprilBio, specifically comprising: 325 vials of remaining MCB, 162 vials of Reference Standard, and 80 vials of Drug Product. The itemized amounts are $415,729.61 for the MCB and $14,398.56 for the Reference Standard, while the Drug Product will be transferred free of charge.

This contract is related to the global technology transfer agreement for APB-R3 (EVO301) that AprilBio signed with Evommune on June 20, 2024. The company explained that since that agreement, it has been sequentially transferring related development and manufacturing materials to support the licensee's clinical development and manufacturing activities.

Meanwhile, the contract takes effect on August 24, 2026, and the payment is scheduled to be made within 30 days of invoice issuance.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.